Mid banner advertisement: BDO
Advertisement: Mogrify
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: RSM
ARM Innovation Hub
Advertisement: China mid banner
Advertisement: EBCam mid banner
Advertisement: Cambridge Network
Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Advertisement EY mid banner
1 May, 2020 - 11:39 By Tony Quested

CDP writes new chapter in development of pen injector for diabetics

A Cambridge UK-Italy collaboration is producing a smart new injector pen for diabetics.

Tech innovator Cambridge Design Partnership is working on the technology with the Stevanato Group in Padua, which has been an industry force since 1949. The new device is based on the Axis-D technology and intellectual property licensed exclusively from injector pen specialist Haselmeier in 2019.

Stevanato Group is a leading producer of glass primary packaging and provider of integrated capabilities for combination products.

CDP says the business alliance strongly supports the expansion of the Stevanato group’s portfolio of devices for patients suffering from diabetes.

The agreement leverages synergistic strengths: on one side, CDP’s leading design and development expertise in drug delivery and on the other, the Stevanato Group’s extensive experience in glass containers, tooling, injection moulding, device assembly – plus its global commercial network.

CDP and the Stevanato Group will be able to offer innovative drug delivery solutions to pharmaceutical customers working together from the first concept right through design development, scale-up, regulatory submission, and commercial-scale production in all global markets.

“We are delighted to be announcing this partnership,” says Uri Baruch, CDP’s head of drug delivery. “The Stevanato Group is well established in the device field as a leading supplier of cartridges and assembly equipment for pen-injectors. It is a pleasure to extend our existing working relationship with them for their pen-injector and to address the needs of patients.”

Paolo Patri, chief technology officer at the Stevanato Group, added: “Our R & D team – with the active support of CDP, an established player in the design and development of drug delivery devices – will offer a competitive pen-injector platform and some customisation options.

“With the resources and experience of both companies we will provide diabetic patients with a product that is easy-to-use, aesthetically appealing, and cost-effective.”

This new collaboration is one of the programmes behind the recent substantial growth of CDP’s team of healthcare-focused designers and engineers in both Cambridge UK and Raleigh, North Carolina in the US.

Newsletter Subscription

Stay informed of the latest news and features